Home / Nicole Watkins

Nicole Watkins

Fulcrum Acquires Global Rights to Losmapimod, a Potential Therapy for Facioscapulohumeral Muscular Dystrophy

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Fulcrum Therapeutics, a biotechnology company focused on discovering and developing therapies to rebalance gene expression, today announced an exclusive worldwide license agreement with GlaxoSmithKline (GSK) for development and commercialization of the investigational drug losmapimod. Fulcrum intends to advance losmapimod into a Phase 2b trial in the rare and …

Read More »

FSD Pharma to Acquire Prismic Pharmaceuticals for $17.5 Million

TORONTO–(BUSINESS WIRE)–FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD Pharma” or the “Company”) and Prismic Pharmaceuticals Inc. (“Prismic”), a US-based specialty R&D pharmaceutical company, announced today that they have entered into a securities exchange agreement dated April 22, 2019 (the “Agreement”) pursuant to which FSD Pharma has agreed …

Read More »

FDA Approves Merck’s Keytruda in Combination with Inlyta as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with Inlyta (axitinib), a tyrosine kinase inhibitor, for the first-line treatment of patients with advanced renal cell carcinoma …

Read More »

Lilly Announces Positive Top-Line Results from its Phase 3 Study Evaluating Taltz in Non-Radiographic Axial Spondyloarthritis

INDIANAPOLIS, April 22, 2019 /PRNewswire/ — Eli Lilly and Company(NYSE: LLY) announced today that Taltz® (ixekizumab) met the primary and all major secondary endpoints in COAST-X, a Phase 3 study evaluating the safety and efficacy of Taltz for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) in patients who are biologic disease-modifying anti-rheumatic drug (bDMARD)-naïve. …

Read More »

Lilly and Avidity Biosciences Enter License and Research Collaboration in Immunology and Other Indications

INDIANAPOLIS and LA JOLLA, Calif., April 22, 2019 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Avidity Biosciences, Inc. today announced a global licensing and research collaboration focused on the discovery, development and commercialization of potential new medicines in immunology and other select indications. The companies will utilize Avidity’s technology platform to progress new therapeutic approaches toward …

Read More »

FDA Permits Marketing of First Medical Device for Treatment of Attention Deficit Hyperactivity Disorder

The U.S. Food and Drug Administration today permitted marketing of the first medical device to treat attention deficit hyperactivity disorder (ADHD). The prescription-only device, called the Monarch external Trigeminal Nerve Stimulation (eTNS) System, is indicated for patients ages 7 to12 years old who are not currently taking prescription ADHD medication …

Read More »

Pfizer and Lilly Announce Top-Line Results from its Long-Term Phase 3 Study of Tanezumab in Osteoarthritis Patients

NEW YORK & INDIANAPOLIS–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg. The objective of the study was to compare the long-term joint safety and 16-week efficacy of tanezumab relative to nonsteroidal anti-inflammatory …

Read More »

Inovio Publishes Cancer Killing Data of Its Transformative DNA-encoded Bi-specific T Cell Engagers in a Peer-reviewed Journal

PLYMOUTH MEETING, Pa., April 18, 2019 /PRNewswire/ — Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the company’s novel DNA-encoded Bi-specific T Cell Engagers (dBiTEs) generated potent anti-tumor activities and cleared established tumors in preclinical studies. Inovio’s dBiTE results were published in a JCI Insight article entitled, “DNA-encoded bi-specific T cell …

Read More »

Viela Bio’s Inebilizumab Receives Breakthrough Therapy Designation from the FDA for Treatment of Neuromyelitis Optica Spectrum Disorder

GAITHERSBURG, Md.–(BUSINESS WIRE)–Viela Bio today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the Company’s anti-CD19 monoclonal antibody inebilizumab, an investigational monotherapy for neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a rare, life-threatening autoimmune disease affecting the central nervous system. “The Breakthrough …

Read More »

Mallinckrodt Reports Top-Line Results from Proof-of-Concept Study of Nitric Oxide Gas in Ex-Vivo System of Human Lung Transplants

STAINES-UPON-THAMES, United Kingdom, April 18, 2019 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced top-line results from its company-sponsored, proof-of-concept study of nitric oxide gas (gNO) with ex-vivo lung perfusion compared to lung perfusion alone in human lung transplants. The study’s primary objectives were …

Read More »